The price of Akero Therapeutics Inc (NASDAQ: AKRO) closed at $21.72 in the last session, down -2.07% from day before closing price of $22.18. On the day, 757560 shares were traded.
Ratios:
We take a closer look at AKRO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 29.27 and its Current Ratio is at 29.27. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on September 19, 2023, initiated with a Overweight rating and assigned the stock a target price of $69.
On August 28, 2023, UBS started tracking the stock assigning a Buy rating and target price of $83.
Morgan Stanley Upgraded its Equal-Weight to Overweight on January 27, 2023, whereas the target price for the stock was revised from $40 to $65.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 01 ’24 when Young Jonathan sold 5,000 shares for $24.38 per share. The transaction valued at 121,913 led to the insider holds 263,306 shares of the business.
Cheng Andrew sold 1,969 shares of AKRO for $55,782 on Mar 13 ’24. The President and CEO now owns 589,447 shares after completing the transaction at $28.33 per share. On Mar 13 ’24, another insider, White William Richard, who serves as the Chief Financial Officer of the company, sold 724 shares for $28.33 each. As a result, the insider received 20,511 and left with 49,630 shares of the company.
Stock Price History:
Over the past 52 weeks, AKRO has reached a high of $58.38, while it has fallen to a 52-week low of $11.25.
Shares Statistics:
A total of 68.95M shares are outstanding, with a floating share count of 57.62M. Insiders hold about 16.42% of the company’s shares, while institutions hold 82.89% stake in the company.
Earnings Estimates
The company has AKRX analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $16.77, with high estimates of $21.72 and low estimates of $11.48.
Analysts are recommending an EPS of between $Healthcare and $Basic Materials for the fiscal current year, implying an average EPS of $Industrials.
